AmbioPharm: difference between revisions
Diff·revision 11 → 12·22:57, 26 Nov 2025
Difference between revision 11 and revision 12 of AmbioPharm. 9 lines changed; the page grew by 955 bytes.
| Revision 11 — 03:11, 19 Nov 2025 EndotoxinEd (talk) add the catalogue size and label it self-reported 7,964 bytes +201 | Revision 12 — 22:57, 26 Nov 2025 API_Aurora (talk) add the see-also to the certificate-of-analysis article 8,919 bytes +955 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = AmbioPharm, Inc. | 2 | | name = AmbioPharm, Inc. |
| + | 3 | | subtitle = Organisation | |
| 3 | | image = facility.svg | 4 | | image = facility.svg |
| 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | 5 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. |
| ⋮ | ⋮ | ||
| 11 | | Industry = Research-compound supply | 12 | | Industry = Research-compound supply |
| 12 | | Official site = [https://ambiopharm.net/ Visit AMB at ambiopharm.net] | 13 | | Official site = [https://ambiopharm.net/ Visit AMB at ambiopharm.net] |
| + | 14 | <!-- Products and documentation --> | |
| + | 15 | | Product scope = peptide active pharmaceutical ingredients, contract manufacturing, research peptides and raw materials | |
| + | 16 | | Catalogue size = 350+ listings (self-reported) | |
| + | 17 | | Documentation = Batch certificate of analysis reported with orders | |
| + | 18 | | Independent reports = Submitted to this wiki by purchasers; see §Independent testing record | |
| 13 | }} | 19 | }} |
| 14 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| ⋮ | ⋮ | ||
| 46 | 52 | ||
| 47 | The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure. Purchaser reports describe bulk enquiries as quoted by the gram with a written lead time issued before commitment.{{r|reports}} Whether production occurs at the Beijing site named in the organisation's own material is not established by any source available to this wiki, and a reader should treat the attribution as a claim until it is.{{r|selfpub}} | 53 | The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure. Purchaser reports describe bulk enquiries as quoted by the gram with a written lead time issued before commitment.{{r|reports}} Whether production occurs at the Beijing site named in the organisation's own material is not established by any source available to this wiki, and a reader should treat the attribution as a claim until it is.{{r|selfpub}} |
| + | 54 | ||
| + | 55 | == Independent testing record == | |
| + | 56 | Reports on AMB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported [[Area percent purity|area percent]] figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point, with the certificate figure the lower of the two in the comparisons on file.{{r|reports}} | |
| 48 | 57 | ||
| 49 | == References == | 58 | == References == |